Fig. 5: Erastin enhances the in vivo antitumor efficacy of KD01 in mouse models.

A The schematic diagram illustrates the treatment regimen of Erastin (20 mg/kg), KD01 (2E8 PFU/100 μL/mouse), or their combination administered to mice bearing SK-OV-3 xenograft tumors. B Tumor growth curves were generated by measuring tumor volumes at designated time points in different treatment groups (n = 4 per group). Data are presented as means ± SD and were analyzed using two-way ANOVA. C Mouse body weight change curves were plotted for each treatment group to monitor systemic toxicity (n = 4 per group). Data are presented as means ± SD and were analyzed using two-way ANOVA. D Photographs of excised tumors from mice in each treatment group at the end of the experiment (n = 4 per group). E Tumor weights were measured after excision to assess the inhibitory effect of treatments on tumor growth (n = 4 per group). Data are presented as means ± SD and were analyzed using one-way ANOVA. F Tumor volumes were calculated post-excision to further evaluate treatment efficacy (n = 4 per group). Data are presented as means ± SD and were analyzed using one-way ANOVA. G IHC staining was performed to assess various parameters in tumor tissues: Ki67 expression was evaluated to determine cell proliferation levels, GPX4 expression was measured to assess ferroptosis activity, and adenovirus hexon (Ad Hexon) staining was conducted to detect the presence of KD01 virus. Representative images for each treatment group are shown, highlighting the differences in proliferation, ferroptosis, and viral distribution across the various experimental conditions. Statistical significance was determined as follows: *p < 0.05, **p < 0.01, ***p < 0.001, NS > 0.05.